Survey of pediatricians in Germany reveals important challenges for possible implementation of meningococcal B vaccination

6Citations
Citations of this article
21Readers
Mendeley users who have this article in their library.

Abstract

Incidence of invasive meningococcal disease is low in Germany at 0.5 cases/100,000 inhabitants. Serogroup B (MenB) is most common, causing 70% of cases, with highest incidence in infants (5.9/100,000). In 2013, a MenB vaccine was licensed in Europe. To assess pediatricians' attitudes towards MenB vaccination and its potential use in Germany we conducted a nationwide cross-sectional survey among 5677 pediatricians. Of 3107 participants (response: 55%), 79.1% would recommend a MenB vaccination to parents, with 66.7% favoring a schedule at 6, 8 and 12 months over 2, 3, 4 and 12 months (13.4%). Administration separately from other vaccines was preferred (63.2%); 38.5% feared that a recommendation would lead to refusal of other recommended vaccinations. In conclusion, pediatricians showed distinct preferences regarding possible integration of MenB vaccination into the existent immunization schedule. As physicians play a crucial role in the implementation, findings will be useful in decision-making regarding potential introduction.

Cite

CITATION STYLE

APA

Takla, A., Wichmann, O., Koch, J., Terhardt, M., & Hellenbrand, W. (2014). Survey of pediatricians in Germany reveals important challenges for possible implementation of meningococcal B vaccination. Vaccine, 32(48), 6349–6355. https://doi.org/10.1016/j.vaccine.2014.09.040

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free